MNKD 250103 6.00C (MNKD250103C6000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

MNKD250103C6000

Watchlist

0.77
+0.24+45.28%

15min DelayClose Jan 2 16:00 ET

0.77High0.77Low

Intraday

5D
Daily

News

MannKind Shares Rise After Wells Fargo Begins Coverage
MT NewswiresDec 20, 2024 14:24 ET
Leerink Partners Maintains MannKind(MNKD.US) With Buy Rating, Announces Target Price $9
Moomoo NewsDec 20, 2024 13:31 ET · Ratings
RBC Capital Upgrades MannKind(MNKD.US) to Buy Rating, Raises Target Price to $10
Moomoo NewsDec 20, 2024 13:31 ET · Ratings
Wells Fargo Initiates MannKind(MNKD.US) With Buy Rating, Announces Target Price $9
Moomoo NewsDec 20, 2024 13:31 ET · Ratings
This S&P Global Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
BenzingaDec 20, 2024 09:52 ET
Wells Fargo Initiates Coverage on MannKind With Overweight Rating, $9 Price Target
MT NewswiresDec 20, 2024 07:55 ET · Ratings

Comments

Stock_Drift

Dec 16, 2024 05:17

$MannKind (MNKD.US)$

Jaguar8

Dec 16, 2024 05:09

NEWS

$MannKind (MNKD.US)$
MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
4 minutes ago, 3:05 AM PST
Via GlobeNewswire
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025
Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression
MannKind (MNKD) announced six-month results from its Phase 3 INHALE-1 study of Afrezza (inhaled insulin) in children and adolescents aged 4-17...

BelleWeather

Nov 22, 2024 05:30

Housekeeping continued…

Surpassed target price and am focusing elsewhere.

Share Your Profit/Loss

BelleWeather

Oct 25, 2024 14:15

Scaling out

of LETFs and contracts…

Share Your Profit/Loss

BelleWeather

Oct 18, 2024 21:03

MannKind

I think this company still has room to grow and may be undervalued, however it is next to being scaling out for other opportunities as the space is crowded and many new therapies have advanced.

Share Your Profit/Loss